Ensysce Biosciences initiates Phase 3 study of PF614

Ensysce Biosciences (ENSC) announced the initiation of its pivotal Phase 3 study of PF614, the Company’s lead product candidate. This study, PF614-301, ‘A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain after Abdominoplasty’ is designed to demonstrate PF614’s ability to effectively manage post-surgical pain while protecting from abuse and offering patients what is believed to be a safer alternative to conventional opioids. The study aims to confirm that PF614 delivers powerful pain relief and facilitates the transition to non-opioid out-patient care. Ensysce has partnered with Rho, Inc., a leading Clinical Research Organization.